Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors

Abstract

A method for treating adult onset neurodegenerative diseases and diabetes by administering an effective dose of Granulocyte-Colony Stimulating Factors.

1 . A method of treating an adult onset neurodegenerative disease in a human, comprising administering a periodic course of an effective dose of Granulocyte-Colony Stimulating Factors.  
   
   
       2 . The method of  claim 1 , wherein said neurodegenerative disease is selected from a group consisting of Parkinson's Disease, macular degeneration, urinary incontinence, Alzheimer's, Multiple Sclerosis and age related memory impairment.  
   
   
       3 . The method of  claim 1 , wherein said Granulocyte-Colony Stimulating Factors is selected from a group consisting of Granulocyte-Colony Stimulating Factor or its derivatives or its derivatives, functionally similar biological or chemical compounds or combinations thereof.  
   
   
       4 . The method of  claim 1 , wherein said treatment maintains the state of disease or reverses one or more symptoms of the disease.  
   
   
       5 . The method of  claim 4 , wherein said symptom is selected from the group consisting of resting tremor, rigidity, postural instability, micrographia, urinary and gastrointestinal incontinence and the sense of smell.  
   
   
       6 . The method of  claim 1 , wherein said effective dose ranging from 0.1 micrograms to 1000 micrograms per kg body weight per day of Granulocyte-Colony Stimulating Factors is administered by injection each day for about 1 to 8 days.  
   
   
       7 . The method of  claim 1 , wherein said period the course of Granulocyte-Colony Stimulating Factor is administered every 2 to 18 weeks.  
   
   
       8 . The method of  claim 1 , wherein said administered is selected from a group consisting of subcutaneous injection, transdermal patch, intravenously, and orally.  
   
   
       9 . A method of reducing blood glucose levels in diabetes in a human, comprising administering a periodic course of an effective dose of Granulocyte-Colony Stimulating Factors.  
   
   
       10 . A method of  claim 9 , wherein said diabetes is Type 1 diabetes or Type 2 diabetes.  
   
   
       11 . The method of  claim 9 , wherein said Granulocyte-Colony Stimulating Factors is selected from a group consisting of Granulocyte-Colony Stimulating Factor or its derivatives, functionally similar biological or chemical compound or combinations thereof.  
   
   
       12 . The method of  claim 9 , wherein said reduced blood glucose levels are less than 110 blood glucose mg/dl.  
   
   
       13 . The method of  claim 12 , wherein said blood glucose levels were reduced for a period of at least 2 days.  
   
   
       14 . The method of  claim 9 , wherein said effective dose ranging from 0.1 micrograms to 20000 micrograms per kg body weight per day of Granulocyte-Colony Stimulating Factors is administered by injection each day for about 1 to 8 days.  
   
   
       15 . The method of  claim 9 , wherein said period course of Granulocyte-Colony Stimulating Factor is administered every 2 to 18 weeks.  
   
   
       16 . The method of  claim 9 , wherein said administered is selected from a group consisting of subcutaneous injection, transdermal patch, intravenously, and orally.  
   
   
       17 . A method for treating adult onset neurodegenerative diseases in a human comprising: 
 a. treating stem cells in vitro with an effective dose of Granulocyte-Colony Stimulating Factors; and    b. injecting an effective amount of said treated stem cells into a human.    
   
   
       18 . The method of  claim 17 , further comprising administering a periodic course of an effective dose of Granulocyte-Colony Stimulating Factors after injection of treated stem cells.  
   
   
       19 . A method for treating adult onset neurodegenerative diseases in a human comprising: 
 a. injecting an effective amount of stem cells into the patient; and    b. administering a periodic course of an effective dose of Granulocyte-Colony Stimulating Factors.    
   
   
       20 . The method of  claim 17  or  19 , wherein said stem cells a selected from a group consisting of harvested umbilical stem cells, adult stem cells, progenitor stem cells or stem cell lines.  
   
   
       21 . A method of any of the preceding claims, further comprising treating said human with an effective dose of a second compound or molecule that enhances or elevates a population of progenitor stem cells or stem cells.  
   
   
       22 . An adult onset Type II diabetic patient having high fasting levels of blood glucose treated with a periodic course of an effective dose ranging from 0.1 micrograms to 1000 micrograms per kg body weight per day of Granulocyte-Colony Stimulating Factor leading to reduction of blood sugar to normal levels, wherein said effective dose is administered from about 1 to 8 days and repeated every 2 to 18 weeks.  
   
   
       23 . An adult patient having reversed symptoms of Parkinson's Disease administered with a periodic course of an effective dose ranging from 0.1 micrograms to 20000 micrograms per kg body weight per day of Granulocyte-Colony Stimulating Factors, wherein said effective dose is administered from about 1 to 8 days and repeated every 2 to 18 weeks.  
   
   
       24 . A method of treating an adult onset neurodegenerative disease in a human, comprising administering a periodic course of an effective dose of Granulocyte-Colony Stimulating Factors.